GlassScriptPhysician profile
Joel H Lee
NPI 1790768877
$510.51
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $45.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $107.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $68.64 | 2019-2020 | |
| Amgen INC. | $57.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $50.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.15 | 2019 | |
| Lilly USA, LLC | $46.09 | 2019-2020 | |
| Pfizer INC. | $39.34 | 2019 | |
| Circassia INC. | $24.43 | 2019 | |
| Shire North American Group INC | $15.55 | 2019 | |
| Allergan, INC. | $14.90 | 2020 | |
| Antares Pharma, INC. | $14.47 | 2019 | |
| Astellas Pharma US INC | $13.70 | 2019 | |
| Novo Nordisk INC | $11.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.